bluuebunny/crossref_metadata_2025_split huggingface dataset:
What Is the prognostic value of osteomedullary uptake on MIBG scan in neuroblastoma patients under one year of age?
Authors: De Cervens Claire Labreveux , Hartmann Olivier , Bonnin François , Couanet Dominique , Valteau‐Couanet Dominique , Lumbroso Jean , Behar Catherine , Martelli Hélène , Lemerle Jean 
Published: February 2007

AbstractTwenty‐seven infants under one year of age with metastatic neuroblastoma were studied for osteomedullary metastases. They were evaluated by at least two imaging procedures: X‐ray films and MIBG scan. Taking into account the results of these investigations, 3 groups were defined: osteomedullary metastases were detected in 8 infants by both X‐ray and MIBG scan, no osteomedulary sites were detected by either technique in 13 patients, and 6 had osteomedullary foci with positive MIBG uptake but no radiological abnormality. These three groups were apparently different in terms of median age, response to chemotherapy, and long‐term survival. The third group, which has not been previously described, appears to have a better prognosis than patients with radiologically detectable bone lesions. Nevertheless it was necessary to use intensive chemotherapy to obtain remission in these particular patients. It should be mandatory to specify the investigatory technique used to describe osteomedullary metastases in infants and treatment should be adapted according to this grouping system. © 1994 Wiley‐Liss, inc.
Stage III abdominal non‐Hodgkin's lymphoma in costa rican children: Comparison of two consecutive trials of treatment
Authors: Lobo‐Sanahuja Francisco , García Ivette , Barrantes José C. , Barrantes Max , Jiménez Rafael , Argüello Ana 
Published: February 2007

AbstractSeventy‐three patients with Stage III abdominal non‐Hodgkin's lymphoma were prospectively treated following two sequential protocols (P): L278 P (group A, 33 patients) (1978‐1983) and L384 P (group B, 40 patients), (1984‐1991). No patient received radiotherapy. The L278 P included 7 drugs: cyclophosphamide, vincristine (VCR), adriamycin (ADR), prednisone, methotrexate (MTX), dexamethasone, and 6‐mercaptopurine, given for remission induction, maintenance, and CNS prophylaxis. In the L384 P we introduced a consolidation phase consisting of intravenous MTX and citrovorum factor rescue, and IV cytosine arabinoside. VCR was also added to the monthly doses and the maintenance phase was reduced from 18 to 15 months. From January 1988 we changed ADR for epirubicin in the same doses. Prophylactic treatment of the CNS, in the L384 P, was intensified by increasing the number of doses of MTX IT in the remission, induction, and consolidation phases, and with the use of ara‐C IT. Laparotomy in 50 patients allowed partial resection in 16, and second‐look laparotomy was performed in 27 patients. Viable tumor was found in four patients. Three patients (G‐A) died from metabolic complications and another 4 (2 G‐A and 2 G‐B) failed to attain CR and died. A total of 28 (85%) of 33 children of G‐A and 38 (95%) of 40 children in G‐B achieved CR. Five children died in remission (2 G‐A, 3 G‐B). Three patients (G‐A) relapsed in the CNS and one (G‐B) relapsed in the abdomen and died. Disease‐free survival at 120 months was 70% in G‐A and 84% in G‐B.
Long‐term disease‐free survival in a child with refractory metastatic malignant germ cell tumor treated by high‐dose chemotherapy with autologous bone marrow rescues
Authors: Devalck Christine , Tempels Didier , Ferster Alina , De Laet Marc‐Henri , Bujan Willem , Heiman Pierre , Sariban Eric 
Published: February 2007

AbstractWe report the case of a 8‐month‐old girl who presented with a metastatic malignant germ cell tumor (MGCT) that proved to be resistant to chemotherapy, including salvage platinum‐based combination therapy, surgery, and metastatectomy. The child was then treated with high‐dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow rescue (ABMR) for two courses, since the first course was well tolerated and resulted in serum α‐f etoprotein normalisation. The child remains in complete remission 3 years post‐ABMR and 4 years post‐diagnosis, with no detectable treatment‐related sequelae. Thus, as already reported in adults, dose‐intensive chemotherapy with ABMR may have curative potential in children with refractory MGCT.
Carney's triad: Apropos of a new case
Authors: Acha Tomás , Picazo Beatriz , García‐Martín Francisco J. , Urda Antonio , Campos Joaquín 
Published: February 2007

AbstractCarney's triad is defined by the coexistence of at least two of three rare disorders, including gastric epithelioid leiomyosarcoma (malignant leiomyoblastoma), pulmonary chondroma, and paraganglioma, most often extra‐adrenal and functioning.We report a new case in a 10‐year‐old girl. The paraganglioma, although nonfunctioning, was detected after it was searched for, as Carney's triad was suspected. Unrelated seems the development of breast fibroadenomas in the same patient.Whenever a patient with one component of the triad is encountered, the possibility of this syndrome should be considered and the other two components sought.
Choroid plexus carcinoma: Report of one case with favourable response to treatment
Authors: Aricáog Maurizio , Raiteri Emanuela , Bossi Grazia , Giordana Maria Teresa , Corbella Franco , Locatelli Davide , Pezzotta Stefano 
Published: February 2007

AbstractChoroid plexus carcinoma (CPC) is a rare tumor with usually severe prognosis, whose optimal treatment has not yet been established. The exact role of complete surgical resection, chemotherapy, and radiotherapy has been debated but not clarified. We report one girl with CPC diagnosed at age 3 months and apparently cured with minimal surgical resection, chemotherapy, and delayed irradiation. At the age of 8 years, she is well, with minor psychomotor retardation and growth hormone deficiency as the only sequelae. © 1994 Wiley‐Liss, Inc.
Hypertensive crises induced by treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazine
Authors: Wu Li‐Teh , Dicpinigaitis Peter , Bruckner Howard , Manger William , Averbuch Steven 
Published: February 2007

AbstractCombination chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD) is an effective treatment regimen for malignant pheochromocytoma. There have not been any significant acute cardiovascular effects reported following CVD treatment. Among seven patients with malignant pheochromocytoma treated with CVD at our institution, two patients with labile hypertension developed hypertensive crises following CVD treatment. The marked increase in blood pressure correlated with an increase in urinary excretion of catecholamine metabolites in one patient. Further hypertensive crises following sebsequent CVD treatments were avoided by optimizing each patient's antiadrenergic therapy. Similar to the approach used preoperatively for patients with resectable pheochromocytoma, maximal antiadrenergic therapy is essential in preventing hypertensive crises in patients with malignant pheochromocytoma undergoing CVD treatment. © 1994 wiley‐Liss, inc.
Peritoneal metastases in two patients with pineoblastoma and ventriculo‐peritoneal shunts
Authors: Gururangan Sridharan , Heideman Richard L. , Kovnar Edward H. , Sanford Robert A. , Kun Larry E. 
Published: February 2007

AbstractWe report the uncommon occurrence of ventriculo‐peritoneal shunt‐associated peritoneal metastases in two patients with pineoblastoma. In one patient, the peritoneal cavity was the only site of recurrence; there was no evidence of disease recurrence in the central nervous system. One other patient with recurrent intracranial disease had synchronous, but asymptomatic, peritoneal metastases which were detected on an elective ultrasound. Although rare, peritoneal metastases appear to respond well to systemic chemotherapy. Ultrasound surveillance of the abdomen should be considered as a part of the routine follow‐up evaluation in patients with embryonal central nervous system tumors and ventriculo‐peritoneal shunts. © 1994 Wiley‐Liss, Inc.
Acute tumour lysis syndrome complicating treatment of stage IVS neuroblastoma in infants under six months old
Authors: Hain Richard D. W. , Rayner Lisa , Weitzman Sheila , Lorenzana Adonis 
Published: February 2007

AbstractAcute tumour lysis syndrome (ATLS) is a common complication of the treatment of haematopoeitic malignancies. It is also well recognized in many nonhaematopoeitic malignancies of adults. There are very few reports of the syndrome occurring during therapy for the nonhaematopoeitic malignancies of childhood, and none has previously been reported in the treatment of neuroblastoma. We report the cases of four patients presenting to The Hospital for Sick Children (HSC) between 1985 and 1992 who developed ATLS during treatment for stage IVS neuroblastoma. ATLS is a significant risk in patients undergoing therapy for stage IVS neuroblastoma, particularly where this has been delayed. © 1994 Wiley‐Liss, Inc.
Isolated bone relapse during hematologic remission in childhood acute lymphoblastic leukemia: Report of a metatarsal relapse and review of the literature
Authors: Murray Jeffrey C. , Gmoser Dean J. , Barnes Douglas A. , Oshman Daniel , Hawkins Hal K. , Gresik Mary V. , Dreyer Zoann E. 
Published: February 2007

AbstractAn 11‐year‐old boy with prior bone marrow and testicular relapses of his acute lymphoblastic leukemia (ALL) developed an isolated metatarsal bone relapse during complete hematologic remission 10 months after completion of chemotherapy. Although there was no radiographic or histologic evidence of additional occult leukemia, the polymerase chain reaction (PCR) technique detected a leukemic clone in both his bone marrow and metatarsal.A literature survey revealed only 10 reported cases of isolated bone relapse occurring during complete bone marrow remission in childhood ALL. Most of these patients had prior bone marrow or extramedullary relapses. The majority experienced subsequent relapses after their isolated bone recurrence. We report a case of isolated bone recurrence, review all previously reported cases, and suggest that PCR elucidation of clonal disease may provide a better understanding of these extremely rare extramedullary events. © 1994 Wiley‐Liss, Inc.
Long‐term outcome of patients with monostotic Ewing's sarcoma treated with combined modality
Authors: Gasparini Marco , Lombardi Fabrizio , Ballerini Emanuela , Gandola Lorenza , Gianni Maria C. , Massimino Maura , Rottoli Luigia , Fossati‐Bellani Franca 
Published: February 2007

AbstractOne hundred and twenty‐one consecutive patients with monostotic Ewing's sarcoma (ES) were treated according to three consecutive combined modality programs from 1974 to 1986. Their 3‐year progression free survival (PFS) rate from diagnosis of 59% was identical to the event free survival (EFS) rate, since all the 50 events occurring within 3 years from diagnosis were tumor recurrences. Primary tumor was treated with radiotherapy in 75 cases, surgical resection plus radiotherapy in 38, and radical surgery in 8. Chemotherapy was given to all patients and each program included adriamycin, vincristine, and cyclophosphamide ± dactinomycin. Median follow‐up was 12 years, ranging from 6 to 19 years. The PFS rate decreased to 49% at 6 years and plateaued at 46% after the 7th year from diagnosis, even though some relapses were observed as late as 14 years from diagnosis. Second malignancies developed in 7 patients free from progressive ES and were represented by osteogenic sarcoma in previously irradiated bone in 4 cases and by breast carcinoma in 3. No other event but tumor relapse or second malignancy occurred in this series. EFS rate was 47% at 6 years and 39% at 12 years, further decreasing in the following years because of a number of late events. A continuous PFS longer than 7 years may be consistent with cure in the majority of patients with monostotic ES. However, these patients should be followed indefinitely because of risk of second malignancies. © 1994 Wiley‐Liss, Inc.
Interphase cytogenetic study of childhood acute lymphoblastic leukemia
Authors: Berger Angelika , Strehl Sabine , Hekele Andreas , Ambros Peter F. , Haas Oskar A. , Gadner Helmut 
Published: February 2007

AbstractWe used the fluorescence in situ hybridization (FISH) technique and centromere‐specific probes for chromosomes 1, 6, 8, 10, 12, 17, 18, X, and Y to investigate the presence and number of the respective chromosomes in interphase nuclei of 14 cases of childhood acute lymphoblastic leukemia (ALL) which were shown to be hyperdiploid by DNA flow cytometry irrespective of their cytogenetic pattern. Numerical anomalies for one or more chromosomes were detected in all 14 cases. The FISH results were compared with those obtained by conventional cytogenetic analysis. A hyperdiploid karyotype was evident in 5 cases, the others were either normal or lacking cytogenetic results because of technical failure. In the 5 cytogenetically hyperdiploid cases, 14 numerical abnormalities were observed with both techniques, whereas 4 numerical deviations were found only with FISH. In 9 other cases which had a DNA content indicating hyperdiploidy, 34 trisomies and 2 tetrasomies were detected by FISH analysis. Furthermore, in 1 case duplication of the Y chromosome and in 3 male cases duplication of the X chromosome were evident. Double‐target FISH experiments in 2 patients allowed the correlation of numerical aberrations of 2 chromosomes in one and the same cell. By such analyses, detection of subpopulations of tumor cells was found to be relatively easy. Our results indicate that the FISH technique with chromosome‐specific repetitive centromeric probes is a rapid, simple to use, and easy to interpret technique for the evaluation of numerical chromosomal aberrations in interphase nuclei of leukemias. © 1994 Wiley‐Liss, Inc.
Intensive conditioning regimen for bone marrow transplantation in children with high‐risk haematological malignancies
Authors: Cole Catherine H. , Pritchard Sheila , Rogers Paul C. J. , Davis Jeffrey E. , Phillips Gordon , Chan Ka Wah 
Published: February 2007

AbstractBetween September 1987 and May 1991, 21 children aged 10 months to 15 years (median 9 years) underwent bone marrow transplantation (BMT) for advanced haematological malignancies using a conditioning regimen consisting of total body irradiation (TBI), etoposide 1.8 g/m2 by continuous infusion, and cyclophosphamide 2 g/m2 on 3 consecutive days. The patients included 14 with acute lymphoblastic leukaemia (ALL), 1 with chronic myeloid leukaemia (CML), 1 with juvenile CML, 4 with non‐Hodgkin's lymphoma and 1 with acute nonlymphocytic leukaemia. Eleven had an allogeneic BMT from an HLA‐matched sibling, and 1 from an unrelated donor. Nine patients received 4‐hydroperoxycyclophosphamide purged autologous marrow. Median time to myeloid engraftment (ANC > 500/μl) was 19 days in allogeneic BMT patients and 28 days in autologous BMT patients (P < .01). Mucositis was the major regimen‐related toxicity (RRT). GI toxicity in the form of diarrhoea affected ten patients and five had veno‐occlusive disease of the liver. Two patients had mild bladder toxicity and one died of renal toxicity. There was no CNS or cardiac toxicity. There was no significant difference in the incidence of toxicity according to the type of BMT (autologous or allogeneic), total dose, or sequence of TBI. With a median follow‐up of 44 months, ten patients are alive (6/12 allogeneic BMT patients and 4/9 autologous BMT patients). Of the 11 deaths, four were related to toxicity (2 aspergillus, 1 haemorrhage following liver biopsy, and 1 from haemolytic‐uraemic syndrome), and 4/12 allogeneic and 4/9 autologous BMT patients died from relapsed disease. This conditioning regimen is well tolerated in children, demonstrating mild and reversible RRT. © 1994 Wiley‐Liss, Inc.
Neurourologic consequences of accidental intrathecal vincristine: A case report
Authors: Zaragoza Michael R. , Ritchey Michael L. , Walter Andrew 
Published: February 2007

AbstractInadvertent intrathecal administration of vincristine results in severe neurotoxicity. Motor and sensory bladder dysfunction have been reported but the long‐term urologic consequences are unknown due to the associated high mortality. We report a case of accidental intrathecal vincristine administration with patient survival and follow‐up of 24 months. The child developed a lower motor neuron neuropathic bladder requiring intermittent self‐catheterization of the bladder. Urinary tract management of these children should be based on the urodynamic findings. © 1995 Wiley‐Liss, Inc.
A simple exam to screen superficial masses: Fine‐needle aspiration cytology
Authors: Gamba P. G. , Messineo A. , Antoniello L. M. , Boccato P. , Blandamura S. , Cecchetto G. , Dall'Igna P. , Guglielmi M. 
Published: February 2007

AbstractFine‐needle aspiration cytology (FNAC) is now considered a useful tool in the evaluation of adult patients with mass lesions. We reviewed the experience with FNAC in our Paediatric Surgical Department.One hundred and eleven FNACs were performed in children with a superficial mass and no definite diagnosis. All the exams were done by the same physician using a fine needle and no anesthesia. We routinely used May‐Grünwald‐Giemsa and Papanicolaou staining. Patients age ranged from 20 days to 17 years, with a mean age of 6.5 years.A clinically benign pathology was cytologically confirmed in 90 cases (81%). All children did well at follow‐up. Malignancy was diagnosed in eight cases (7.2%) and in all was confirmed with a surgical biopsy. In nine children (8.1%) the specimen was considered insufficient for definite diagnosis. In four cases (3.6%) the pathologist diagnosed a possible malignancy that was excluded at surgical biopsy. The sensitivity was 100% and the specificity was 96%.Our experience confirms that FNAC is a fast, cheap, simple, and accurate diagnostic method and should be used for screening in all children with doubtful superficial masses. © 1995 Wiley‐Liss, Inc.
Survival after retinoblastoma: Long‐term consequences and family history of cancer
Authors: Byrne Julianne , Fears Thomas R. , Whitney Charles , Parry Dilys M. 
Published: February 2007

AbstractRetinoblastoma (Rb) is a rare childhood tumor of the eye. In the heritable form, tumors are often bilateral and survivors have a greatly increased risk both for a second malignancy and for having children with Rb. Familial patterns of both cancer and birth defects are poorly understood in families with a heritable cancer, and little is known of the ways that a heritable cancer affects the lives of long‐term survivors. To find out more about these and other issues in the lives of long‐term survivors of childhood and adolescent cancer, we interviewed 56 adult survivors of retinoblastoma (15 with the heritable form) and 84 brothers and sisters as controls, who formed part of a large retrospective cohort study. Rb survivors were interviewed between 1980 and 1983, when they were 30 years old on average. Types of employment and health problems did not differ between survivors and controls, regardless of sight, but the income of blind survivors was considerably less than that of partially sighted survivors. Despite similar marriage rates, fewer survivors than controls reported a pregnancy (RR = 0.45; 95% Cl; 0.24–0.83 for both sexes combined). Parents of children with heritable Rb seemed more likely to have had cancer than parents in families with nonheritable Rb (P = 0.06), and mothers were more likely than fathers to be affected (P = 0.01).This small series suggests that having retinoblastoma may have many long‐term consequences, reaching beyond genetic and physical effects to touch family life and income attainment and the health of other family members. Follow‐up of more modern cohorts and the use of molecular tools will clarify the long‐term consequences of more recent therapies, and patterns of familiar cancer. © 1995 Wiley‐Liss, Inc.
Carboplatin in childhood Medulloblastoma/PNET: Feasibility of an in vivo sensitivity test in an “up‐front” study
Authors: Mastrangelo Renato , Lasorella Anna , Riccardi Riccardo , Colosimo Cesare , Iavarone Antonio , Tornesello Assunta , Mastrangelo Stefano , Ausili‐Cefaro Giampiero , Di Rocco Concezio 
Published: February 2007

AbstractSixteen patients with high risk MB/PNET at diagnosis were included in a pilot study employing carboplatin (CBDCA) as a single drug prior to conventional therapy. The main goal of the study was to identify in a short‐term trial a significant response that would predict further response to CBDCA in the single patient. Exploration of CBDCA activity was focused on response after the first course as compared to the response following the second course. A course consisted of CBDCA 600 mg/m2 on days 1 and 2 administered in a 1 h infusion to be repeated 3–4 weeks later. After two cycles we observed 1 CR and 9 PR, that is a 62% response rate. The first course resulted in 5 PR, 5 MR, 5 SD, and 1 PD; after the subsequent course in all responding patients, response persisted or improved whereas in no patient with SD any improvement was observed. The correlation of response to the first course with response to the second course was statistically significant (P = 0.0009). The main toxicity of the single course was hematologic and consisted of rapidly reversible grade 3–4 neutropenia and thrombocytopenia in 94% of patients. Pharmacokinetic studies showed a very limited interpatient variability of both Cmax (57.6 ± 9.9 μg/ml) and AUC (15.3 ± 1.5 mg/ml · min) of free CBDCA, which eliminates an important variable in the evaluation of response. In conclusion, this “in vivo test” appears effective, reasonably safe, and reproducible in identifying patients likely to benefit from CBCDA: after a period of time as short as 3–4 weeks following the first course, multidrug chemotherapy including CBDCA may be employed in the responding patients, whereas an alternative regimen would be indicated in the non‐responding patients. © 1995 Wi1ey‐Liss Inc.
Effect of trimethoprim‐sulphamethoxazole in langerhans' cell histiocytosis: Preliminary observations
Authors: Tzortzatou‐Stathopoulou Fotini , Xaidara Athina , Mikraki Vasiliki , Moschovi Mary , Arvanitis Dimitris , Ageloyianni Panagoula , Prodromou Phivos 
Published: February 2007

AbstractTwenty‐three children with Langerhans' cell histiocytosis (LCH) have been treated with trimethoprim‐sulphamethoxazole (T‐S) in a 4‐year period. The children are classified in two main groups according to the extent of their disease. Group A includes 16 children with single system disease and group B, seven children with multisystem disease. All patients were treated for 4 weeks to 3 months. The results of treatment are evaluated in terms of response in individual organs involved. All children with single system disease had a good response to the drug. Children with multisystem disease had a good response to some organs but a poorer outcome for the lungs and for the blood. These patients did not respond even to conventional chemotherapy. © 1995 Wiley‐Liss, Inc.